The global drug delivery devices market size is expected to reach USD 403.6 billion by 2030, registering a CAGR of 5.83% during the forecast period, according to a new report by Grand View Research, Inc. Growing prevalence of cancer, neurological disorders, diabetes, and other infectious diseases is expected to drive the adoption of drug delivery devices in the coming years. In addition, increasing product launches for various applications such as ophthalmology, neurology, and oncology are also expected to propel the market growth. Growing adoption of wearable drug delivery devices for its usage in home-care settings is also expected to drive the market.
Hydrogel is one of the prominent drug delivery vehicles and includes supramolecular hydrogels, DNA hydrogels, bio-inspired hydrogels, multi-functional and stimuli-responsive hydrogels. These advanced hydrogels are used for various applications such as ophthalmic, oral, intestinal, cardiac illness, and cancer. Similarly, other vehicles such as liposomes, nanoparticles, and micelle are also being developed for various applications.
Key players present in the market are adopting various strategies such as mergers and acquisitions, partnership, and collaborations to develop and improve drug delivery devices for various applications. Moreover, end-users are also forming partnerships with companies to acquire drug delivery devices for training purpose and research studies. In addition, market players are also forming distribution agreement to expand the reach of their products. Therefore, alliances made by the players are expected to drive the market growth during the forecast period.
Drug Delivery Devices Market Report Highlights
- The oral route of administration segment held largest share in 2023 mainly due to its easy usage and low cost
- The injectable route of administration segment is expected to experience the fastest growth during the forecast period mainly due to growing advancements in injectable devices for accuracy
- Drug delivery devices for central nervous system disorders are expected to experience fastest growth rate mainly due to growing development of blood brain barrier drug delivery devices for the treatment of neurological disorders
- In 2023, North America dominated the global space with the largest revenue share owing to the adoption of drug delivery devices in the region and increasing product launches in the countries such as U.S.
- Asia Pacific is expected to grow at fastest growth rate during the forecast period mainly due to growing development and advancement in drug delivery devices in the region and presence of large patient pool.
Get Sample Copy of Drug Delivery Devices Market
Drug Delivery Devices Market Segmentation
Grand View Research has segmented the global drug delivery devices market based on route of administration, application, end-use, and region:
Route of Administration Outlook (Volume, Units; Revenue, USD Billion, 2018 - 2030)
- Oral
- Inhalation
- Transdermal
- Injectable
- Ocular
- Nasal
- Topical
- Others
Application Outlook (Volume, Units; Revenue, USD Billion, 2018 - 2030)
- Oncology
- Infectious Diseases
- Respiratory Diseases
- Diabetes
- Cardiovascular Diseases
- Autoimmune Diseases
- Central Nervous System Disorders
- Others
End-use Outlook (Volume, Units; Revenue, USD Billion, 2018 - 2030)
- Hospitals
- Diagnostic Centers
- Ambulatory Surgery Centers/Clinics
- Home Care Settings
- Others
Regional Outlook (Volume, Units; Revenue, USD Billion, 2018 - 2030)
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Key Players in the Drug Delivery Devices Market
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Hoffmann-La Roche, Ltd.
- Novartis AG
- BD
- Bayer AG
- uniQure N.V.
- Sibiono GeneTech Co. Ltd.
Order a free sample PDF of the Drug Delivery Devices Market Intelligence Study, published by Grand View Research.